Table 3 Effect of different treatments on PI3K/AKT/mTOR signaling pathway gene expression of Caco-2.

From: In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of PI3K/AKT/mTOR pathway

Tested gene

Untreated cells

Trial 4

Trial 15

Trial 16

Trial 20

PI3K

833.6 ± 10.3c

33.69 ± 3.9b

6.1 ± 1.03a

10.2 ± 1.38a

8.05 ± 2.03a

P53

0.21 ± 0.003a

11.58 ± 1.77b

44.16 ± 5.7c

15.86 ± 3.88b

24.2 ± 7.38b

BCl2

165.3 ± 1.59e

105.98 ± 14.6d

0.89 ± 0.002a

54.32 ± 12.3c

8.93 ± 0.041b

mTOR

850.8 ± 23.19e

437.8 ± 16.8d

6.35 ± 0.78a

157.43 ± 13.78c

21.58 ± 1.7b

AKT

134.71 ± 8.97e

33.45 ± 2.47c

0.981 ± 0.02a

43.56 ± 1.78d

21.3 ± 4.78b

PGC1α

209.3 ± 3.12e

50.36 ± 12c

2.78 ± 0.07a

98.3 ± 11.89d

9.68 ± 0.1b

VEGF

22.3 ± 0.98d

8.73 ± 0.08b

3.78 ± 0.23a

14.65 ± 1.9c

7.89 ± 0.08b

PTEN

0.125 ± 0.005a

22.39 ± 5.71b

156.3 ± 3.69d

55.69 ± 8.9c

43.89 ± 12.3c